📰 Mark Oki News
Page 3 - Mark Oki News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Oki. Real-time updates on events, politics, business and more.
February 23, 2023
Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q2 Results Conference Call. At this time, all participants are on a listen-only mode. . Please note this conference is being recorded.
February 21, 2023
ENGLEWOOD, CO / ACCESSWIRE / February 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription
January 5, 2023
ENGLEWOOD, CO / ACCESSWIRE / January 5, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription
November 30, 2022
Adzenys XR-ODT Total Prescription (TRx) Unit Growth Driven by a Combination of Continued Sales Force Execution, Leveraging of the Aytu RxConnect Patient Support Program, and a Positive Response to the
November 22, 2022
ENGLEWOOD, CO / ACCESSWIRE / November 22, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused
November 17, 2022
Ranked 94th Fastest Growing Company in North AmericaRanked 21st Fastest Growing Life Sciences CompanyENGLEWOOD, CO / ACCESSWIRE / November 17, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU)
November 7, 2022
ENGLEWOOD, CO / ACCESSWIRE / November 7, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription
October 13, 2022
Following a corporate review, Aytu BioPharma is indefinitely suspending clinical development and removing expenses related to AR101/enzastaurin, Healight, and NT0502, and focusing on revenue growth and
October 5, 2022
Adzenys XR-ODT is FDA-Approved as Bioequivalent to Adderall XRReported Supply Disruptions of Adderall XR Generic Equivalents Have the Potential to Affect Patient Access to ADHD MedicationsENGLEWOOD, CO
September 27, 2022
27.09.2022 - Record fourth quarter and fiscal year net revenue driven by strong growth in Prescription segmentPositive Adjusted EBITDA within Prescription segmentCompany to Host Conference Call Today at 4:30pm ETENGLEWOOD, CO / ACCESSWIRE / September 27, 2022 / ...